Abiola Bolarinwa

Abiola Bolarinwa

Auto-generated profile, based on publicly available information

Abiola Bolarinwa

Division of Hematology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MRMatthew James Rees
Matthew James Rees
AMAytaj Mammadzadeh
Aytaj Mammadzadeh
ABAbiola Bolarinwa
Abiola Bolarinwa
MEMohammed E. Elhaj
Mohammed E. Elhaj
ABArwa Bohra
Arwa Bohra
SKShaji Kumar
Shaji Kumar
Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023. We identified 339 individuals (1-exposure = 297, 2-exposures = 38, 3-exposures = 4) who received 385 BDTs (ADC = 59, TCE = 134, CAR-T = 192), with median follow-up of 21-months. ADC recipients were older, with more lines of therapy (LOT), and penta-refractory disease. Compared to ADCs, CAR-T (aHR = 0.29, 95%CI = 0.20–0.43) and TCEs (aHR = 0.62, 95%CI = 0.43–0.91) had better progression-free survival (PFS) on analysis adjusted for age, the presence of extramedullary (EMD), penta-refractory disease, multi-hit high-risk cytogenetics, prior BDT, and the number of LOT in the preceding 1-year. Likewise, compared to ADCs, CAR-T (aHR = 0.28, 95%CI = 0.18–0.44) and TCEs (aHR = 0.60, 95%CI = 0.39–0.93) had superior overall survival. Prior BDT exposure negatively impacted all classes but was most striking in CAR-T, ORR 86% vs. 50% and median PFS 13-months vs. 3-months. Of relapses, 54% were extramedullary in nature, and a quarter of these cases had no history of EMD. CAR-T demonstrates superior efficacy and where feasible, should be the initial BDT. However, for patients with prior BDT or rapidly progressive disease, an alternative approach may be preferable.

18 February 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
Saurabh ZanwarSaurabh Zanwar
Saurabh Zanwar
DJDragan Jevremovic
Dragan Jevremovic
PKPrashant Kapoor
Prashant Kapoor
HOHoratiu Olteanu
Horatiu Olteanu
FBFrancis Buadi
Francis Buadi
SKShaji Kumar
Shaji Kumar
Risk stratification models based on cytogenetics and disease burden help identify high-risk patients with newly diagnosed multiple myeloma (NDMM). However, some high-risk patients remain undetected. This study evaluated the prognostic utility of the proportion of clonal plasma cells in the S-phase of the cell cycle for NDMM. Patients with active multiple myeloma diagnosed between 01/01/2013 and 01/31/2023 who underwent S-phase assessment were included. The S-phase proportion was calculated by analyzing DNA content between G0/G1 and G2/M peaks. Among 823 patients, 16% (135) had S-phase ≥2% at diagnosis. Patients with S-phase ≥2% exhibited significantly worse median progression-free survival (PFS) of 1.4 years (95% CI: 1.2–1.9) compared to 2.9 years (95% CI: 2.6–3.3) for those with S-phase <2% (HR 1.6, p < 0.0001). Median overall survival (OS) was also significantly lower at 3.9 years (95% CI: 2.9–5.7) versus 9.2 years (95% CI: 7.9–not reached; HR 2.2, p < 0.0001). Multivariate analysis confirmed S-phase ≥2% as an independent predictor of inferior PFS (HR 1.56, p = 0.001) and OS (HR 2, p < 0.0001) after adjusting for R2-ISS risk, age, renal function, and treatment strategies. Among patients with S-phase ≥2%, 53% (68/129) experienced progression-free survival (PFS) under 18 months with upfront therapy. Elevated S-phase was associated with a 2.5-fold higher risk of progression within 18 months [OR 2.55 (95% CI: 1.7–3.7), p < 0.001]. Patients with elevated S-phase but no IMS-high risk had a median OS of 5.7 years (95% CI: 4.7–9.2), similar to the IMS-high risk cohort without elevated S-phase (5.4 years, 95% CI: 4–NR). Those with both elevated S-phase and IMS-high risk had significantly worse OS (3.1 years, 95% CI: 1.6–NR, p = 0.043). These findings suggest that S-phase ≥2% is a powerful, independent prognostic marker for NDMM.

4 April 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
ABAbiola Bolarinwa
Abiola Bolarinwa
MNMadhu Nagaraj
Madhu Nagaraj
Saurabh ZanwarSaurabh Zanwar
Saurabh Zanwar
NANadine Abdallah
Nadine Abdallah
PBP. Leif Bergsagel
P. Leif Bergsagel
SKShaji Kumar
Shaji Kumar
Venetoclax (Ven), a BCL-2 inhibitor, has demonstrated efficacy in patients with relapsed/refractory multiple myeloma (RRMM) harboring a t(11;14) and/or elevated BCL-2 expression. However, data from clinical trial remain inconclusive. This retrospective study evaluated the efficacy and safety of Ven-based therapies in 232 MM patients without concurrent AL amyloidosis treated at Mayo Clinic sites between Jan 2015 and Dec 2023. The median age was 62 years, with a median of 3 prior lines of therapy. Among the cohort, 82% had t(11;14), and elevated BCL-2 expression was identified in 17 of 18 non-t(11;14) patients tested. Ven combinations included Ven-Dex (VenD; 48.3%), Proteasome Inhibitor-Ven (30.2%), and Daratumumab-Ven (19%) with other combinations making up the rest. The overall response rate was 57%; 64% for t(11;14) patients and 26% for non-t(11;14) patients. Median progression-free survival (PFS) was 9.4 months overall; 11.8 months for t(11;14) patients and 2.9 months for those without (p < 0.001). Among t(11;14) patients, the presence of del(17p) or 1q gain/amplification significantly reduced PFS to 7.7 months. Venetoclax-based regimens remain an important option for t(11;14) patients, but efficacy is limited in patients without a t(11;14). The presence of secondary high-risk cytogenetics imparts an inferior PFS.

31 May 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
ABAbiola Bolarinwa
Abiola Bolarinwa
LOLateef Odukoya
Lateef Odukoya
FBFrancis Buadi
Francis Buadi
VRVincent Rajkumar
Vincent Rajkumar
SKShaji Kumar
Shaji Kumar
JCJoselle M Cook
Joselle M Cook
People of African descent have a reported higher incidence of multiple myeloma (MM) and increased prevalence of its precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Despite this, research focusing on people of African descent remains sparse. Even in the absence of robust studies across African populations, major disparities are consistently reported. West Africans and South African Black men have a higher prevalence of MGUS than individuals of European descent. MM has been shown to occur in African individuals at a younger age of diagnosis compared to European individuals, with a relatively higher proportion of females (M/F ∼1 vs. 1.4 in Europeans), delayed diagnosis (symptoms to diagnosis 10-12 months), and a higher prevalence of bone disease at presentation. This review summarizes the existing literature on monoclonal gammopathies for African people and highlights critical gaps in our understanding of the disease within the diverse African population. Importantly, differences in disease biology, with respect to cytogenetic and immunologic differences, which contribute to disparate disease outcomes are discussed. Concerted efforts to bridge knowledge gaps through collaborative research initiatives, both within and beyond the African continent, are urgently needed.

6 October 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AAAli Alsugair
Ali Alsugair
EMEstefania Gauto Mariotti
Estefania Gauto Mariotti
MAMohammad M. Alhousani
Mohammad M. Alhousani
SFSaubia Fathima
Saubia Fathima
MYMuhammad Yousuf
Muhammad Yousuf
ATAyalew Tefferi
Ayalew Tefferi
Allogeneic stem cell transplant (ASCT) remains the only curative option in chronic myelomonocytic leukemia (CMML). We retrospectively analyzed 138 CMML patients who underwent ASCT at the Mayo Clinic. Patients who transitioned to ASCT while in chronic phase (Group A) displayed superior post-transplant survival (PTS), compared to those in whom ASCT was performed after blast transformation (BT; Group B) (median 95 vs. 16 months; p = 0.01). In Group A, PTS was superior in patients with <5% bone marrow (BM) blasts at time of ASCT (median 164 vs. 13.5 months; p = 0.01). Other predictors of superior PTS included day-100 BM blast <5% or normal cytogenetics (median 164 vs. 18 months; p = 0.01) or presence of chronic graft-versus-host-disease (GVHD; median 164 vs. 26 months; p = 0.01). Pre-ASCT hypomethylating agent exposure (HR = 2.03; p = 0.03), and receiving more than one line of pre-ASCT chemotherapy (p = 0.01) predicted inferior PTS. In multivariable analysis, predictors of superior GVHD-free and relapse-free survival (GRFS) included the use of myeloablative conditioning and the absence of morphologically or cytogenetically apparent disease at day-100. The use of post-transplant cyclophosphamide (PTCy) was associated with a higher cumulative incidence of relapse (p = 0.02) and numerically inferior PTS (p = 0.1). Group B patients also appeared to benefit from achieving BM blast <5% at the time of ASCT (p = 0.4) as well as at day-100 (p = 0.01), in terms of PTS, while full chimerism and normal cytogenetics at day-100 were associated with superior GRFS. These observations support the value of ASCT in CMML, especially if performed prior to BT and in the presence of <5% BM blasts at the time of ASCT. Additionally, the observed detrimental impact of PTCy requires additional studies to confirm and investigate the underlying mechanisms.

4 October 2025 in American Journal of Hematology
Verified
Journal Article
Closed access
ABAbiola Bolarinwa
Abiola Bolarinwa
Saurabh ZanwarSaurabh Zanwar
Saurabh Zanwar
NANadine Abdallah
Nadine Abdallah
FBFrancis K. Buadi
Francis K. Buadi
SHSuzanne R. Hayman
Suzanne R. Hayman
SKShaji K. Kumar
Shaji K. Kumar